

Stefan Leucht

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4757850/stefan-leucht-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

417
papers

31,200
citations

87
h-index

169
g-index

484
ext. papers

37,675
ext. citations

6.9
avg, IF

7.31
L-index

#	Paper	IF	Citations
417	Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.. <i>Lancet Psychiatry,the</i> , 2022 ,	23.3	4
416	Early- and subsequent- response of cognitive functioning in AlzheimerB disease: Individual-participant data from five pivotal randomized clinical trials of donepezil.. <i>Journal of Psychiatric Research</i> , 2022 , 148, 159-164	5.2	0
415	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.. <i>JAMA Psychiatry</i> , 2022 ,	14.5	5
414	Cognitive impairment networks in AlzheimerB disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil.. <i>European Neuropsychopharmacology</i> , 2022 , 57, 50-58	1.2	2
413	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe.. <i>Neuropsychiatric Disease and Treatment</i> , 2022 , 18, 201-219	3.1	1
412	About the issue of including or excluding studies from China in systematic reviews.. <i>Schizophrenia Research</i> , 2022 , 240, 162-163	3.6	0
411	Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.. <i>Lancet, The</i> , 2022 , 399, 824-836	40	11
410	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.. <i>Molecular Autism</i> , 2022 , 13, 10	6.5	3
409	Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 815718	5	1
408	Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.. <i>Lancet Psychiatry,the</i> , 2022 , 9, 232-242	23.3	1
407	Relapse prevention in schizophrenia - AuthorsPreply.. <i>Lancet Psychiatry,the</i> , 2022 , 9, e14	23.3	
406	Confidence of evidence should be considered in ranking of treatments in the network meta-analysis - AuthorsPreply.. <i>Lancet Psychiatry,the</i> , 2022 , 9, e16	23.3	
405	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.. <i>Lancet Psychiatry,the</i> , 2022 , 9, 291-306	23.3	2
404	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends.. <i>Neuroscience and Biobehavioral Reviews</i> , 2022 , 136, 104608	9	5
403	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.. <i>Schizophrenia Research: Cognition</i> , 2022 , 29, 100249	2.8	3
402	What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Analyses of a Phase III Clinical Trial.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 816339	5	
401	New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment.. <i>Schizophrenia Research</i> , 2021 , 239, 192-199	3.6	0

400	Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. <i>Evidence-Based Mental Health</i> , 2021 , 24, 56-61	11.1	5
399	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2021 , 8, 969-980	23.3	26
398	Associations between individual antipsychotics and the risk of arrests and convictions of violent and other crime: a nationwide within-individual study of 74 925 persons. <i>Psychological Medicine</i> , 2021 , 1-9	6.9	3
397	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , 2021 , 229, 3-11	3.6	2
396	An efficient way to assess the effect of COVID-19 on mental health in the general population. <i>Lancet Psychiatry</i> , 2021 , 8, e14-e15	23.3	2
395	The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study. <i>Schizophrenia Research</i> , 2021 , 231, 100-107	3.6	3
394	Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. <i>Frontiers in Pharmacology</i> , 2021 , 12, 688950	5.6	3
393	Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. <i>Neuropsychopharmacology</i> , 2021 , 46, 2320-2329	8.7	2
392	Let us not rush back to odds ratios without a recommendation to convert them to interpretable measures. <i>Journal of Clinical Epidemiology</i> , 2021 , 134, 172-173	5.7	
391	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
390	Antipsychotic drugs: from major tranquilizers to Neuroscience-based Nomenclature. <i>Psychological Medicine</i> , 2021 , 51, 522-524	6.9	5
389	Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021 , 271, 293-302	5.1	5
388	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , 2021 , 78, 270-280	14.5	33
387	Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient Perspectives. <i>Pharmacopsychiatry</i> , 2021 , 54, 53-59	2	1
386	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. <i>Schizophrenia Bulletin</i> , 2021 , 47, 672-681	1.3	2
385	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021 , 64, e7	6	3
384	Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. <i>European Psychiatry</i> , 2021 , 64, e16	6	1
383	Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions. <i>Schizophrenia Research</i> , 2021 , 228, 425-434	3.6	3

382	Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2021 , 10, 214	3	3
381	Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis. <i>JAMA Psychiatry</i> , 2021 , 78, 1238-1248	14.5	4
380	Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1651-1660	4	1
379	Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. <i>Schizophrenia Bulletin</i> , 2021 , 47, 1601-1610	1.3	2
378	Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 1075-1084	4.3	0
377	Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. <i>Translational Psychiatry</i> , 2021 , 11, 487	8.6	7
376	Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , 2021 , 237, 20-25	3.6	1
375	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021 , 47, 986-996	1.3	0
374	Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia. <i>Brain</i> , 2020 , 143, 3495-3505	11.2	5
373	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020 , 46, 1439-1458	1.3	12
372	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMISE trial. <i>Psychiatry Research</i> , 2020 , 289, 112970	9.9	2
371	T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS [PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S308-S308	1.3	78
370	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2020 , 7, 581-601	23.3	58
369	Antipsychotics for schizophrenia and substance misuse - Authors Preply. <i>Lancet, The</i> , 2020 , 395, 1903	4.0	
368	Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. <i>Schizophrenia Bulletin</i> , 2020 , 46, 496-504	1.3	8
367	How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , 2020 , 20, 102	4.2	12
366	Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2020 , 17, 100537	1.8	6
365	Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2020 , 18, 443-455	1.1	6

364	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020 , 270, 83-94	5.1	3
363	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. <i>American Journal of Psychiatry</i> , 2020 , 177, 342-353	11.9	65
362	M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA: A META-REGRESSION ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020 , 46, S212-S213	1.3	78
361	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMISE trial. <i>Schizophrenia Research</i> , 2020 , 223, 271-278	3.6	3
360	Optimal Dose of Selective Serotonin Reuptake Inhibitors, Venlafaxine, and Mirtazapine in Major Depression: A Systematic Review and Dose-Response Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2020 , 18, 211-219	1.1	3
359	What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials. <i>Lancet Psychiatry</i> , 2020 , 7, 1004-1006	23.3	2
358	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2020 , 8, CD008016	3.6	14
357	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. <i>Molecular Autism</i> , 2020 , 11, 66	6.5	15
356	Antipsychotic drugs barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2020 , 50, 2622-2633	6.9	4
355	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. <i>European Neuropsychopharmacology</i> , 2020 , 34, 76-86	1.2	14
354	Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence. <i>BMJ Open</i> , 2020 , 10, e035073	3	2
353	Optimal dosing of antidepressant drugs - AuthorsPreply. <i>Lancet Psychiatry</i> , 2019 , 6, 806-807	23.3	1
352	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMISE cohort study. <i>Translational Psychiatry</i> , 2019 , 9, 20	8.6	30
351	Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis. <i>JAMA Psychiatry</i> , 2019 , 76, 1063-1073	14.5	32
350	Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. <i>Lancet Psychiatry</i> , 2019 , 6, 601-609	33.3	99
349	17.1 PREDICTORS OF RELAPSE IN FIRST EPISODE PSYCHOSIS PATIENTS IN REMISSION. <i>Schizophrenia Bulletin</i> , 2019 , 45, S115-S116	1.3	78
348	The controversy about cognitive behavioural therapy for schizophrenia. <i>World Psychiatry</i> , 2019 , 18, 235-244	2.6	13
347	Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. <i>Brain</i> , 2019 , 142, 1813-1826	11.2	32

346	Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. <i>Neuropsychopharmacology</i> , 2019 , 44, 1589-1596	8.7	15
345	17.4 STRATIFICATION AND PREDICTION OF REMISSION IN FIRST-EPISEODE PSYCHOSIS PATIENTS: THE OPTIMISE COHORT STUDY. <i>Schizophrenia Bulletin</i> , 2019 , 45, S116-S117	1.3	78
344	Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models. <i>BMC Medical Research Methodology</i> , 2019 , 19, 33	4.7	3
343	How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2019 , 45, 639-646	1.3	41
342	Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2019 , 6, 753-765	23.3	15
341	Pharmakotherapie der therapieresistenten Schizophrenie. <i>PSYCH Up2date</i> , 2019 , 13, 223-240	0.1	
340	Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. <i>Neuropsychopharmacology</i> , 2019 , 44, 1955-1966	8.7	9
339	Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2019 , 394, 939-951	40	504
338	Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. <i>European Neuropsychopharmacology</i> , 2019 , 29, 1003-1022	1.2	24
337	Schizophrenien und andere psychotische Störungen 2019 , 301-362.e7		
336	Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies. <i>Biological Psychiatry</i> , 2019 , 85, 573-583	7.9	51
335	Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2019 , 29, 32-45	1.2	33
334	Maximizing response to first-line antipsychotics in schizophrenia: a review focused on findings from meta-analysis. <i>Psychopharmacology</i> , 2019 , 236, 545-559	4.7	26
333	Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain. <i>Pharmacopsychiatry</i> , 2019 , 52, 16-23	2	5
332	Translating the BDI and BDI-II into the HAMD and vice versa with equipercetile linking. <i>Epidemiology and Psychiatric Sciences</i> , 2019 , 29, e24	5.1	20
331	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2018 , 391, 1357-1366	40	1283
330	Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 137, 450-458	6.5	29
329	Antidepressants might work for people with major depression: where do we go from here?. <i>Lancet Psychiatry</i> , 2018 , 5, 461-463	23.3	12

328	Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018 , 268, 625-639	5.1	86
327	Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. <i>Evidence-Based Mental Health</i> , 2018 , 21, 1-3	11.1	20
326	Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2018 , 8, e019280	3	6
325	Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. <i>Schizophrenia Research</i> , 2018 , 193, 23-28	3.6	21
324	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , 2018 , 44, 603-619	1.3	99
323	Translating the HAM-D into the MADRS and vice versa with equipercentile linking. <i>Journal of Affective Disorders</i> , 2018 , 226, 326-331	6.6	25
322	Auditory hallucinations across the lifespan: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2018 , 48, 879-888	6.9	71
321	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , 2018 , 5, CD011883	3.2	6
320	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. <i>The Cochrane Library</i> , 2018 , 5, CD011884	5.2	4
319	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018 , 5, 797-807	23.3	100
318	31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018 , 44, S50-S51	1.3	0
317	In Reply. <i>Deutsches Arzteblatt International</i> , 2018 , 115, 68-69	2.5	
316	Clozapine versus olanzapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018 ,	5.2	1
315	Clozapine versus quetiapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018 ,	5.2	78
314	Clozapine versus risperidone for people with schizophrenia. <i>The Cochrane Library</i> , 2018 ,	5.2	78
313	S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT). <i>Schizophrenia Bulletin</i> , 2018 , 44, S342-S342	1.3	78
312	Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , 2018 , 18, 380	4.2	13
311	Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2018 , 16, 420-429	1.1	89

310	Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 138, 281-288	6.5	32
309	Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. <i>World Psychiatry</i> , 2018 , 17, 316-329	14.4	64
308	Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2018 , 28, 1360-1370	1.2	18
307	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , 2018 , 17, 330-340	14.4	73
306	60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response. <i>Schizophrenia Research</i> , 2018 , 201, 315-323	3.6	17
305	Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. <i>European Neuropsychopharmacology</i> , 2018 , 28, 659-674	1.2	59
304	Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?. <i>World Psychiatry</i> , 2018 , 17, 166-167	14.4	8
303	Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. <i>Lancet Psychiatry</i> , 2018 , 5, 653-663 ^{23,3}	42	
302	What does the MADRS mean? Equipercntile linking with the CGI using a company database of mirtazapine studies. <i>Journal of Affective Disorders</i> , 2017 , 210, 287-293	6.6	27
301	Combining randomized and non-randomized evidence in network meta-analysis. <i>Statistics in Medicine</i> , 2017 , 36, 1210-1226	2.3	70
300	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017 , 16, 77-89	14.4	109
299	Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. <i>Lancet, The</i> , 2017 , 389, 1074-1078 _{1,2}		
298	Markov model for longitudinal studies with incomplete dichotomous outcomes. <i>Pharmaceutical Statistics</i> , 2017 , 16, 122-132	1	2
297	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. <i>JAMA Psychiatry</i> , 2017 , 74, 675-684	14.5	94
296	Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. <i>American Journal of Psychiatry</i> , 2017 , 174, 927-942	11.9	227
295	Clozapine in treatment-resistant schizophrenia. <i>British Journal of Psychiatry</i> , 2017 , 210, 299	5.4	4
294	A novel approach to measuring response and remission in schizophrenia in clinical trials. <i>Schizophrenia Research</i> , 2017 , 190, 123-128	3.6	4
293	DSM-III-R change in definition might have affected placebo response to antidepressants - AuthorsP reply. <i>Lancet Psychiatry</i> , 2017 , 4, 22-23	23.3	1

292	Living systematic reviews: 4. Living guideline recommendations. <i>Journal of Clinical Epidemiology</i> , 2017 , 91, 47-53	5.7	81
291	Living systematic review: 1. Introduction-the why, what, when, and how. <i>Journal of Clinical Epidemiology</i> , 2017 , 91, 23-30	5.7	211
290	Living systematic reviews: 2. Combining human and machine effort. <i>Journal of Clinical Epidemiology</i> , 2017 , 91, 31-37	5.7	156
289	Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. <i>Lancet Psychiatry</i> , 2017 , 4, 859-867	23.3	20
288	Living systematic reviews: 3. Statistical methods for updating meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2017 , 91, 38-46	5.7	74
287	Do antipsychotic drugs lose their efficacy for relapse prevention over time?. <i>British Journal of Psychiatry</i> , 2017 , 211, 127-129	5.4	24
286	Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. <i>Lancet Psychiatry</i> , 2017 , 4, 694-705	23.3	66
285	Clinical relevance of findings in trials of CBT for depression. <i>European Psychiatry</i> , 2017 , 45, 207-211	6	15
284	Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. <i>Evidence-Based Mental Health</i> , 2017 , 20, 88-94	11.1	44
283	Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. <i>BMJ Open</i> , 2017 , 7, e016608	3	11
282	How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2017 , 27, 835-844	1.2	57
281	Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 187-198	5.1	11
280	The Prevalence of Mental Illness in Homeless People in Germany. <i>Deutsches Arzteblatt International</i> , 2017 , 114, 665-672	2.5	26
279	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie 2017 , 1321-1338		
278	Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review. <i>Journal of Alzheimers Disease</i> , 2017 , 55, 1583-1594	4.3	28
277	The SWITCH study: rationale and design of the trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016 , 266, 513-21	5.1	4
276	Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant. <i>Journal of Clinical Epidemiology</i> , 2016 , 69, 161-9	5.7	13
275	Use of Clozapine in Schizophrenia-Reply. <i>JAMA Psychiatry</i> , 2016 , 73, 1098-1099	14.5	

274	Dose Equivalents for Antipsychotic Drugs: The DDD Method. <i>Schizophrenia Bulletin</i> , 2016 , 42 Suppl 1, S90-4	1.3	221
273	Valproate for schizophrenia. <i>The Cochrane Library</i> , 2016 , 11, CD004028	5.2	23
272	Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials. <i>Schizophrenia Research</i> , 2016 , 178, 17-22	3.6	39
271	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Focus (American Psychiatric Publishing)</i> , 2016 , 14, 378-386	1.1	1
270	Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. <i>Lancet, The</i> , 2016 , 388, 881-90	4.0	343
269	Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. <i>American Journal of Psychiatry</i> , 2016 , 173, 876-86	11.9	115
268	Second-generation antipsychotics and quality of life in schizophrenia. <i>Lancet Psychiatry, the</i> , 2016 , 3, 694-695	2.3	3
267	Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review. <i>BMC Research Notes</i> , 2016 , 9, 218	2.3	11
266	The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. <i>Harvard Review of Psychiatry</i> , 2016 , 24, 118-28	4.1	73
265	Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. <i>JAMA Psychiatry</i> , 2016 , 73, 199-210	14.5	170
264	Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. <i>European Psychiatry</i> , 2016 , 32, 16-20	6	14
263	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 210-20	3.8	2
262	Behandlungsresistenz 2016 , 157-176		2
261	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie 2016 , 1-18		
260	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. <i>BMJ Open</i> , 2016 , 6, e010919	3	105
259	Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. <i>Lancet Psychiatry, the</i> , 2016 , 3, 935-946	23.3	100
258	Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. <i>Lancet Psychiatry, the</i> , 2016 , 3, 1059-1066	23.3	112
257	AuthorsPreply. <i>British Journal of Psychiatry</i> , 2016 , 209, 171-2	5.4	

256	Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. <i>The Cochrane Library</i> , 2015 , 1, CD009831	5.2	41
255	Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. <i>Neuropsychopharmacology</i> , 2015 , 40, 1742-51	8.7	134
254	Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. <i>Schizophrenia Research</i> , 2015 , 164, 122-6	3.6	7
253	Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. <i>Journal of Affective Disorders</i> , 2015 , 180, 179-84	6.6	178
252	Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. <i>Schizophrenia Bulletin</i> , 2015 , 41, 584-96	1.3	28
251	The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. <i>Schizophrenia Bulletin</i> , 2015 , 41, 549-58	1.3	38
250	CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 152-60	3.2	23
249	Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. <i>Schizophrenia Bulletin</i> , 2015 , 41, 1397-402	1.3	127
248	Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination. <i>BMC Medicine</i> , 2015 , 13, 82	11.4	34
247	Perphenazine for schizophrenia. <i>The Cochrane Library</i> , 2015 , CD003443	5.2	6
246	How effective are common medications: a perspective based on meta-analyses of major drugs. <i>BMC Medicine</i> , 2015 , 13, 253	11.4	52
245	Wirksamkeit von Psychotherapie und Pharmakotherapie. <i>InFo Neurologie & Psychiatrie</i> , 2015 , 17, 34-41	○	
244	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , 2015 ,	5.2	2
243	Accounting for uncertainty due to fast observation carried forward/Poutcome imputation in a meta-analysis model. <i>Statistics in Medicine</i> , 2015 , 34, 742-52	2.3	4
242	Lithium for schizophrenia. <i>The Cochrane Library</i> , 2015 , CD003834	5.2	21
241	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. <i>The Cochrane Library</i> , 2015 ,	5.2	2
240	Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. <i>JAMA Psychiatry</i> , 2015 , 72, 14-21	14.5	69
239	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015 , 172, 617-29	11.9	111

238	Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. <i>Pharmacogenomics</i> , 2015 , 16, 5-22	2.6	13
237	Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms. <i>Schizophrenia Research</i> , 2015 , 162, 169-74	3.6	22
236	Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. <i>Acta Psychiatrica Scandinavica</i> , 2015 , 131, 185-96	6.5	160
235	Schizophrenien und andere psychotische Störungen 2015 , 349-412		
234	Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. <i>Schizophrenia Bulletin</i> , 2014 , 40, 192-213	1.3	281
233	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD006569	2.3	40
232	Bipolar treatment efficacy - AuthorsPreply. <i>Lancet Psychiatry,the</i> , 2014 , 1, 418-9	23.3	
231	Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. <i>Evidence-Based Mental Health</i> , 2014 , 17, 33-7	11.1	77
230	Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD009369	5.2	5
229	Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. <i>Genetic Testing and Molecular Biomarkers</i> , 2014 , 18, 20-31	1.6	26
228	Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD009396	5.2	9
227	Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. <i>Schizophrenia Bulletin</i> , 2014 , 40, 181-91	1.3	240
226	Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry,the</i> , 2014 , 1, 351-9	23.3	207
225	Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1046-55	1.2	17
224	Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. <i>Schizophrenia Research</i> , 2014 , 156, 107-14	3.6	16
223	Dose equivalents for second-generation antipsychotics: the minimum effective dose method. <i>Schizophrenia Bulletin</i> , 2014 , 40, 314-26	1.3	211
222	META-ANALYSES ON DOUBLE-BLIND RCTS ADDING DRUGS WITH ANTI-INFLAMMATORY PROPERTIES TO ANTIPSYCHOTIC MEDICATION. <i>Schizophrenia Research</i> , 2014 , 153, S15-S16	3.6	78
221	Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. <i>Journal of Clinical Psychiatry</i> , 2014 , 75 Suppl 1, 8-14	4.6	87

220	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD009230	5.2	11
219	Perazine for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD002832	5.2	1
218	Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD009227	5.2	3
217	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD009268	5.2	12
216	Carbamazepine for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD001258	5.2	12
215	Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2014 , 12, 192-204	1.1	1
214	Pharmakotherapie der therapieresistenten Schizophrenie. <i>PSYCH Up2date</i> , 2014 , 8, 281-297	0.1	1
213	Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 130, 40-5	6.5	3
212	Equipercntile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1767-72	1.2	34
211	An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios. <i>Statistics in Medicine</i> , 2014 , 33, 2275-87	2.3	30
210	A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation. <i>Acta Psychiatrica Scandinavica</i> , 2014 , 130, 326-41	6.5	28
209	Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. <i>JAMA Psychiatry</i> , 2014 , 71, 706-15	14.5	174
208	Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices. <i>International Clinical Psychopharmacology</i> , 2014 , 29, 224-8 ²	2.2	19
207	Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. <i>Journal of Psychopharmacology</i> , 2014 , 28, 387-94	4.6	24
206	Addressing missing outcome data in meta-analysis. <i>Evidence-Based Mental Health</i> , 2014 , 17, 85-9	11.1	44
205	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2013 , CD006569		14
204	Imputation of response rates from means and standard deviations in schizophrenia. <i>Schizophrenia Research</i> , 2013 , 151, 209-14	3.6	16
203	Clozapine resistance--augmentation strategies. <i>European Neuropsychopharmacology</i> , 2013 , 23, 338	1.2	6

202	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2013 , 150, 328-33	3.6	38
201	The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1010-6	1.2	10
200	Efficacy of antipsychotic drugs for schizophrenia - AuthorsPreply. <i>Lancet, The</i> , 2013 , 382, 1874-5	4.0	5
199	PsychiatristsPdecision making between branded and generic drugs. <i>European Neuropsychopharmacology</i> , 2013 , 23, 686-90	1.2	14
198	The deceleration capacity - a new measure of heart rate variability evaluated in patients with schizophrenia and antipsychotic treatment. <i>European Psychiatry</i> , 2013 , 28, 81-6	6	22
197	Attaining and sustaining remission of predominant negative symptoms. <i>Schizophrenia Research</i> , 2013 , 143, 60-4	3.6	11
196	Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. <i>Schizophrenia Research</i> , 2013 , 145, 125-7	3.6	30
195	Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1023-33 ^{1.2}	4.2	44
194	Can we inflate effect size and thus increase chances of producing "positive" results if we raise the baseline threshold in schizophrenia trials?. <i>Schizophrenia Research</i> , 2013 , 144, 105-8	3.6	
193	Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms. <i>European Neuropsychopharmacology</i> , 2013 , 23, 1051-6	1.2	15
192	Equipercntile linking of the BPRS and the PANSS. <i>European Neuropsychopharmacology</i> , 2013 , 23, 956-9	1.2	81
191	What does the HAMD mean?. <i>Journal of Affective Disorders</i> , 2013 , 148, 243-8	6.6	114
190	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet, The</i> , 2013 , 382, 951-62	4.0	1665
189	Quetiapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2013 , CD006625 ^{5.2}	5.2	41
188	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , 2013 , 18, 53-66	15.1	105
187	Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain. <i>Journal of Clinical Psychopharmacology</i> , 2013 , 33, 74-9	1.7	28
186	MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 2103-9	5.8	33
185	Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. <i>Clinical Trials</i> , 2013 , 10, 378-88	2.2	34

184	Critical trial-related criteria in acute schizophrenia studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012 , 262, 151-5	5.1	5
183	Amitriptyline versus placebo for major depressive disorder. <i>The Cochrane Library</i> , 2012 , 12, CD009138	5.2	25
182	Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. <i>Lancet, The</i> , 2012 , 379, 2063-71	4.0	574
181	Antipsychotic drugs for relapse prevention in schizophrenia [AuthorsPreply. <i>Lancet, The</i> , 2012 , 380, 1056-40		
180	Equipercntile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. <i>European Neuropsychopharmacology</i> , 2012 , 22, 501-5	1.2	20
179	Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. <i>European Neuropsychopharmacology</i> , 2012 , 22, 812-7	1.2	10
178	PatientsPacceptance of the deltoid application of risperidone long-acting injection. <i>European Neuropsychopharmacology</i> , 2012 , 22, 897-901	1.2	6
177	Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. <i>Schizophrenia Bulletin</i> , 2012 , 38, 167-77	1.3	191
176	Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia. <i>Schizophrenia Research</i> , 2012 , 141, 168-72	3.6	19
175	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2012 , CD008015	5.2	92
174	Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1003-11	1.3	120
173	Benzodiazepines for schizophrenia. <i>The Cochrane Library</i> , 2012 , 11, CD006391	5.2	32
172	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. <i>British Journal of Psychiatry</i> , 2012 , 200, 97-106	5.4	257
171	Caregivers of patients with frontotemporal lobar degeneration: a review of burden, problems, needs, and interventions. <i>International Psychogeriatrics</i> , 2012 , 24, 1368-86	3.4	51
170	Haloperidol versus first generation antipsychotics for schizophrenia 2012 ,		10
169	Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. <i>Molecular Diagnosis and Therapy</i> , 2012 , 16, 93-8	4.5	5
168	Schizophrenien und andere psychotische Störungen 2012 , 347-419		
167	Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. <i>Biological Psychiatry</i> , 2011 , 69, 495-503	7.9	108

166	Evidence-based pharmacotherapy of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011 , 14, 269-84	5.8	72
165	Ventajas y desventajas del tratamiento de combinaci3n con antipsic3ticos. Reuni3n ECNP Consensus, marzo de 2008, Niza. <i>Psiquiatria Biologica</i> , 2011 , 18, 55-67	0.2	2
164	Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. <i>Schizophrenia Research</i> , 2011 , 126, 212-9	3.6	22
163	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011 , 10, 138-51	14.4	489
162	Risperidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2011 , CD006626	5.2	58
161	Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. <i>Schizophrenia Research</i> , 2011 , 127, 83-92	3.6	318
160	Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. <i>European Psychiatry</i> , 2011 , 26, 297-301	6	48
159	Second-generation antipsychotics and constipation: a review of the literature. <i>European Psychiatry</i> , 2011 , 26, 34-44	6	88
158	Drowning in numbers-what psychiatrists mean when talking to patients about probabilities of risks and benefits of medication. <i>European Psychiatry</i> , 2011 , 26, 130-1	6	0
157	Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia 2011 ,		5
156	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia 2011 ,		5
155	Trifluoperazine versus low-potency first generation antipsychotic drugs for schizophrenia 2011 ,		5
154	Flupenthixol versus low-potency first generation antipsychotic drugs for schizophrenia 2011 ,		8
153	Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia 2011 ,		7
152	"How to speak to your psychiatrist": shared decision-making training for inpatients with schizophrenia. <i>Psychiatric Services</i> , 2011 , 62, 1218-21	3.3	62
151	How to obtain NNT from Cohen's d: comparison of two methods. <i>PLoS ONE</i> , 2011 , 6, e19070	3.7	94
150	Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. <i>BMC Gastroenterology</i> , 2011 , 11, 17	3	69
149	The clinical significance of cognition-focused interventions for cognitively impaired older adults: a systematic review of randomized controlled trials. <i>International Psychogeriatrics</i> , 2011 , 23, 1364-75	3.4	57

148	Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. <i>Neuropsychopharmacology</i> , 2011 , 36, 375-89	8.7	202
147	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011 , 10, 52-77	14.4	1288
146	Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses. <i>Psychological Medicine</i> , 2011 , 41, 2651-9	6.9	36
145	Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 1616-27	4.6	36
144	Spätschizophrenie und chronische Schizophrenie im höheren Lebensalter 2011 , 241-262		
143	The PANSS should be rescaled. <i>Schizophrenia Bulletin</i> , 2010 , 36, 461-2	1.3	48
142	Second-generation antipsychotics for anxiety disorders. <i>The Cochrane Library</i> , 2010 , CD008120	5.2	33
141	Opioid antagonists for alcohol dependence. <i>The Cochrane Library</i> , 2010 ,	5.2	80
140	Second-generation antipsychotics for major depressive disorder and dysthymia. <i>The Cochrane Library</i> , 2010 , CD008121	5.2	52
139	Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. <i>Biological Psychiatry</i> , 2010 , 68, 86-92	7.9	48
138	Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2010 , 123, 225-33	3.6	481
137	Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. <i>Pharmacogenomics Journal</i> , 2010 , 10, 20-9	3.5	83
136	Amisulpride versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010 , CD006624	4.2	20
135	How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?. <i>European Neuropsychopharmacology</i> , 2010 , 20, 276-9	1.2	18
134	Second-generation antipsychotics for obsessive compulsive disorder. <i>The Cochrane Library</i> , 2010 , CD008141	4.1	36
133	Clozapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010 , CD006633	5.2	115
132	Acamprosate for alcohol dependence. <i>The Cochrane Library</i> , 2010 , CD004332	5.2	160
131	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010 , CD006654	5.2	87

130	Quetiapine versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2010 , CD006625		33
129	Zotepine versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2010 , CD006628		8
128	Zotepine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010 , CD006628	5.2	5
127	Correlation between amygdala volume and age in bipolar disorder - a systematic review and meta-analysis of structural MRI studies. <i>Psychiatry Research - Neuroimaging</i> , 2010 , 182, 1-8	2.9	62
126	Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. <i>Dialogues in Clinical Neuroscience</i> , 2010 , 12, 393-407	5.7	114
125	Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?. <i>Pharmacogenomics Journal</i> , 2009 , 9, 395-403	3.5	37
124	Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. <i>Schizophrenia Bulletin</i> , 2009 , 35, 443-57	1.3	301
123	A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. <i>American Journal of Psychiatry</i> , 2009 , 166, 152-63	11.9	389
122	DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. <i>Pharmacogenomics Journal</i> , 2009 , 9, 71-7	3.5	25
121	Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. <i>Schizophrenia Bulletin</i> , 2009 , 35, 789-97	1.3	57
120	Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. <i>Depression and Anxiety</i> , 2009 , 26, 922-9	8.4	88
119	How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. <i>Molecular Psychiatry</i> , 2009 , 14, 429-47	15.1	347
118	Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 7-14	6.5	146
117	How to read and understand and use systematic reviews and meta-analyses. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 443-50	6.5	35
116	Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. <i>Psychological Medicine</i> , 2009 , 39, 1591-602	6.9	132
115	Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. <i>European Neuropsychopharmacology</i> , 2009 , 19, 520-32	1.2	101
114	Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. <i>Lancet, The</i> , 2009 , 373, 31-41	4.0	1385
113	Are new drugs for schizophrenia better than old ones? [Authors' Reply]. <i>Lancet, The</i> , 2009 , 373, 1249-1250	4.0	4

112	Ziprasidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2009 , CD006623.2	3.2	33
111	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD006569		51
110	Second-generation antipsychotic drugs for anxiety disorders 2009 ,		1
109	Sertindole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2009 , CD006752.5.2	5.2	12
108	Maintenance treatment with antipsychotic drugs for schizophrenia 2009 ,		3
107	CATIE findings revisited. <i>Psychiatric Services</i> , 2009 , 60, 125-6	3.3	4
106	Spätschizophrenie und chronische Schizophrenie im höheren Lebensalter 2009 , 199-219		
105	Therapieresistente Schizophrenie (ICD-10 F2) 2009 , 117-130		
104	Schizophrenien und andere psychotische Störungen 2009 , 411-490		1
103	An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia. <i>Medical Psychiatry</i> , 2009 , 164-173		1
102	Commentary on strategies for switching antipsychotics. <i>BMC Medicine</i> , 2008 , 6, 18	11.4	7
101	Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. <i>Schizophrenia Research</i> , 2008 , 98, 318-22	3.6	86
100	Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. <i>Schizophrenia Research</i> , 2008 , 101, 312-9	3.6	46
99	Comparative remission rates of schizophrenic patients using various remission criteria. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 1643-51	5.5	33
98	Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 1987-93	5.5	22
97	Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. <i>Journal of Psychopharmacology</i> , 2008 , 22, 11-23	4.6	186
96	Haloperidol versus chlorpromazine for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , 2008 , 34, 813-53	5.3	8
95	Haloperidol versus chlorpromazine for schizophrenia. <i>The Cochrane Library</i> , 2008 , CD004278	5.2	35

94	Valproate for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2008 , CD004028		41
93	Personality disorders and violence. <i>Current Opinion in Psychiatry</i> , 2008 , 21, 84-92	4.9	69
92	Cochrane Schizophrenia Group. <i>Schizophrenia Bulletin</i> , 2008 , 34, 259-65	1.3	8
91	Unanswered questions in schizophrenia clinical trials. <i>Schizophrenia Bulletin</i> , 2008 , 34, 302-9	1.3	18
90	Methodological issues in current antipsychotic drug trials. <i>Schizophrenia Bulletin</i> , 2008 , 34, 275-85	1.3	63
89	Issues in psychopharmacology. <i>Schizophrenia Bulletin</i> , 2008 , 34, 258	1.3	2
88	Psychiatric treatment guidelines: doctors non-compliance or insufficient evidence?. <i>Acta Psychiatrica Scandinavica</i> , 2007 , 115, 417-9	6.5	17
87	Physical illness and schizophrenia: a review of the literature. <i>Acta Psychiatrica Scandinavica</i> , 2007 , 116, 317-33	6.5	444
86	On the concept of remission in schizophrenia. <i>Psychopharmacology</i> , 2007 , 194, 453-61	4.7	42
85	Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. <i>Schizophrenia Bulletin</i> , 2007 , 33, 183-91	1.3	156
84	Defining response in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. <i>Neuropsychopharmacology</i> , 2007 , 32, 1903-10	8.7	143
83	Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia. <i>Evidence-Based Mental Health</i> , 2007 , 10, 56	11.1	
82	Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia. <i>Evidence-Based Mental Health</i> , 2007 , 10, 112	11.1	2
81	Benzodiazepines for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2007 , CD006391		56
80	Pretrial medication bias in randomized antipsychotic drug trials. <i>American Journal of Psychiatry</i> , 2007 , 164, 1266; author reply 1266-7	11.9	2
79	Lithium for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2007 , CD003834		49
78	Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. <i>Archives of General Psychiatry</i> , 2007 , 64, 442-55		176
77	Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders. <i>Evidence-Based Mental Health</i> , 2007 , 10, 46	11.1	

76	Aripiprazole versus other atypical antipsychotics for schizophrenia 2007 ,			1
75	Amisulpride versus other atypical antipsychotics for schizophrenia 2007 ,			1
74	Clozapine versus other atypical antipsychotics for schizophrenia 2007 ,			2
73	Olanzapine versus other atypical antipsychotics for schizophrenia 2007 ,			2
72	The attitude of patients towards antipsychotic depot treatment. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 275-82	2.2		75
71	Carbamazepine for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2007 , CD001258			25
70	Early prediction of antipsychotic nonresponse among patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 352-60	4.6		92
69	Shared decision making and long-term outcome in schizophrenia treatment. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 992-7	4.6		110
68	Physical Illness and Schizophrenia: A Review of the Evidence 2007 ,			25
67	How long do psychiatrists wait for response before they switch to another antipsychotic?. <i>Psychopharmacology Bulletin</i> , 2007 , 40, 149-54	0.9		
66	Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. <i>American Journal of Psychiatry</i> , 2006 , 163, 185-94	11.9		322
65	The concepts of remission and recovery in schizophrenia. <i>Pharmacopsychiatry</i> , 2006 , 39, 161-70	2		94
64	The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. <i>Neuropsychopharmacology</i> , 2006 , 31, 406-12	8.7		100
63	Intramuscular haloperidol and olanzapine begin to reduce psychosis within 24 hours. <i>Evidence-Based Mental Health</i> , 2006 , 9, 9	11.1		
62	Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. <i>Pharmacogenomics</i> , 2006 , 7, 159-66	2.6		52
61	ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. <i>Clinical Chemistry</i> , 2006 , 52, 893-5	5.5		51
60	Linking the PANSS, BPRS, and CGI: clinical implications. <i>Neuropsychopharmacology</i> , 2006 , 31, 2318-25	8.7		223
59	Perazine for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD002832			1

58	Dr. Hamann and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2006 , 163, 937-937	11.9	
57	Antidepressants for the negative symptoms of schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD005581		38
56	Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2006 , 21 Suppl 2, S1-10	2.2	5
55	Psychiatric decision making in the adoption of a new antipsychotic in Germany. <i>Psychiatric Services</i> , 2006 , 57, 700-3	3.3	11
54	Standardized remission criteria in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006 , 113, 91-5	6.5	189
53	Eleven-year clinical outcome of schizophrenia in Bali. <i>Acta Psychiatrica Scandinavica</i> , 2006 , 114, 68; author reply 68-9	6.5	
52	Shared decision making for in-patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006 , 114, 265-73	6.5	220
51	Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1813-4	4.6	51
50	Attitudes of psychiatrists toward antipsychotic depot medication. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1948-53	4.6	110
49	Clinical implications of Brief Psychiatric Rating Scale scores. <i>British Journal of Psychiatry</i> , 2005 , 187, 366-374		667
48	European psychiatric treatment guidelines: is the glass half full or half empty?. <i>European Psychiatry</i> , 2005 , 20, 554-8	6	12
47	Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. <i>Biological Psychiatry</i> , 2005 , 57, 1543-9	7.9	190
46	What does the PANSS mean?. <i>Schizophrenia Research</i> , 2005 , 79, 231-8	3.6	889
45	Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. <i>Schizophrenia Research</i> , 2005 , 80, 85-97	3.6	60
44	Dr. Correll and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2005 , 162, 405-a-406	11.9	1
43	Perphenazine for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2005 , CD003443		18
42	Benperidol for schizophrenia. <i>The Cochrane Library</i> , 2005 , CD003083	5.2	2
41	How do psychiatrists choose among different antipsychotics?. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 851-4	2.8	11

40	Is there a differential efficacy of new generation antipsychotic drugs?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005 , 9, 154-6	2.4	
39	Do patients with schizophrenia wish to be involved in decisions about their medical treatment?. <i>American Journal of Psychiatry</i> , 2005 , 162, 2382-4	11.9	172
38	Physicians and patients' involvement in relapse prevention with antipsychotics in schizophrenia. <i>Psychiatric Services</i> , 2005 , 56, 1448-50	3.3	11
37	Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. <i>Clinical Chemistry</i> , 2005 , 51, 376-85	5.5	139
36	Medical decision making in the mental health field. <i>Psychiatric Services</i> , 2005 , 56, 221	3.3	4
35	Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. <i>American Journal of Psychiatry</i> , 2004 , 161, 414-25	11.9	566
34	Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. <i>Clinical Chemistry</i> , 2004 , 50, 1623-33	5.5	110
33	Amisulpride is an "atypical" antipsychotic associated with low weight gain. <i>Psychopharmacology</i> , 2004 , 173, 112-5	4.7	32
32	Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. <i>Schizophrenia Research</i> , 2004 , 70, 33-7	3.6	60
31	Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. <i>Journal of Clinical Epidemiology</i> , 2004 , 57, 1124-30	5.7	135
30	Language bias in neuroscience—is the Tower of Babel located in Germany?. <i>European Psychiatry</i> , 2004 , 19, 230-2	6	11
29	Medical decision making in antipsychotic drug choice for schizophrenia. <i>American Journal of Psychiatry</i> , 2004 , 161, 1301-4	11.9	38
28	Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7 Suppl 1, S15-20	5.8	38
27	Lithium for Schizophrenia Revisited. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 177-186	4.6	51
26	Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 756-65	4.6	5
25	Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 177-86	4.6	8
24	Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists. <i>Pharmacopsychiatry</i> , 2003 , 36, 309-12	2	6
23	Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. <i>American Journal of Psychiatry</i> , 2003 , 160, 1209-22	11.9	365

22	Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. <i>Pharmacopsychiatry</i> , 2003 , 36, 18-26	2	21
21	Shared decision making in psychiatry. <i>Acta Psychiatrica Scandinavica</i> , 2003 , 107, 403-9	6.5	190
20	New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. <i>Lancet, The</i> , 2003 , 361, 1581-9	40	500
19	New generation versus conventional antipsychotics. <i>Lancet, The</i> , 2003 , 362, 404-405	40	3
18	The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. <i>Journal of Clinical Psychiatry</i> , 2003 , 64 Suppl 12, 5-19	4.6	100
17	Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. <i>American Journal of Psychiatry</i> , 2002 , 159, 180-90	11.9	334
16	Carbamazepine augmentation for schizophrenia: how good is the evidence?. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 218-24	4.6	31
15	Dropout rates in randomised antipsychotic drug trials. <i>Psychopharmacology</i> , 2001 , 155, 230-3	4.7	131
14	The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysis. <i>Schizophrenia Bulletin</i> , 2001 , 27, 73-92	1.3	426
13	Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. <i>Clinica Chimica Acta</i> , 2001 , 308, 33-41	6.2	84
12	Doxepin plasma concentrations: is there really a therapeutic range?. <i>Journal of Clinical Psychopharmacology</i> , 2001 , 21, 432-9	1.7	20
11	Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. <i>Psychopharmacology</i> , 2000 , 147, 378-83	4.7	28
10	Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. <i>Schizophrenia Research</i> , 1999 , 35, 51-68	3.6	696
9	Results of treatment of schizophrenia: is the glass half full or half empty?. <i>International Clinical Psychopharmacology</i> , 1999 , 14 Suppl 3, S11-4	2.2	15
8	Variability of cerebral blood flow deficits in 99mTc-HMPAO SPECT in patients with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 1997 , 104, 689-701	4.3	7
7	Accuracy and reproducibility of the measurement of actively circulating blood volume with an integrated fiberoptic monitoring system. <i>Critical Care Medicine</i> , 1995 , 23, 885-93	1.4	57
6	Monitoring of right ventricular function using a conventional slow response thermistor catheter. <i>Intensive Care Medicine</i> , 1994 , 20, 348-53	14.5	13
5	Evidence-based pharmacotherapy of schizophrenia 18-38		1

4	Examining side effect variation in antipsychotic treatment and schizophrenia spectrum disorders		1
3	Metabolic Adverse Effects Associated with Antipsychotic Medications577-597		
2	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. <i>Schizophrenia Bulletin Open,</i>	2.2	2
1	Antipsychotic combinations for schizophrenia		2